<p>Tema Etfs LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Syndax Pharmaceuticals, Inc.（NASDAQ:SNDX - 免费报告）的股份增加了 307.7%。该机构投资者在本季度额外收购了 65,132 股后，持有该公司 86,301 股股票。Tema Etfs LLC 在最近一个季度末持有 Syndax Pharmaceuticals 约 0.10% 的股份，价值 808,000 美元。</p>
<p>获取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
<p>其他大型投资者最近也买卖了该公司的股票。富兰克林资源公司在第二季度将其在 Syndax Pharmaceuticals 的股份增加了 14.5%。富兰克林资源公司现在拥有 2,359,677 股该公司的股票，价值 22,098,000 美元，此前在上个季度额外购买了 298,272 股。Geode Capital Management LLC 在第二季度将其在 Syndax Pharmaceuticals 的股份增加了 1.3%。Geode Capital Management LLC 现在拥有 2,049,350 股该公司的股票，价值 19,195,000 美元，此前在此期间额外购买了 26,365 股。Aisling Capital Management LP 在第二季度将其在 Syndax Pharmaceuticals 的股份增加了 28.5%。Aisling Capital Management LP 现在拥有 1,316,806 股该公司的股票，价值 12,325,000 美元，此前在上个季度额外购买了 291,806 股。Algert Global LLC 在第一季度将其在 Syndax Pharmaceuticals 的持股增加了 12.6%。Algert Global LLC 现在拥有 884,600 股该公司的股票，价值 10,867,000 美元，此前在此期间额外收购了 98,968 股。最后，Candriam S.C.A. 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 49.9%。Candriam S.C.A. 现在拥有 675,085 股该公司的股票，价值 6,322,000 美元，此前在此期间额外收购了 224,650 股。</p>
<h2>Syndax Pharmaceuticals 股票上涨 2.9%</h2>
<p>SNDX 周五开盘价为 20.32 美元。该公司的债务与股本比率为 2.78，流动比率为 4.64，速动比率为 4.42。Syndax Pharmaceuticals, Inc. 的 12 个月最低价为 8.58 美元，最高价为 20.59 美元。该股票的市值为 17.7 亿美元，市盈率为 -5.63，贝塔值为 0.48。该公司的 50 日简单移动平均线为 16.30 美元，200 日简单移动平均线为 13.57 美元。</p>
<p>Syndax Pharmaceuticals（NASDAQ:SNDX - 获取免费报告）上次发布季度财报是在 11 月 3 日星期一。该公司报告的每股收益（EPS）为（0.70）美元，超过了市场共识预期的（0.74）美元，超出 0.04 美元。该公司在本季度的收入为 4587 万美元，而分析师预期为 4908 万美元。Syndax Pharmaceuticals 的股本回报率为 -160.60%，净利润率为 -279.31%。与去年同期相比，Syndax Pharmaceuticals 的收入增长了 266.4%。在去年同期，该公司每股收益为（0.98）美元。平均而言，股票分析师预计 Syndax Pharmaceuticals, Inc. 在当前财政年度的每股收益将为 -3.72 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家研究公司最近对 SNDX 进行了评论。巴克莱将 Syndax Pharmaceuticals 的股票目标价从 22.00 美元上调至 35.00 美元，并在 11 月 24 日的研究报告中给予该公司 “增持” 评级。高盛集团将 Syndax Pharmaceuticals 的股票目标价从 20.00 美元上调至 24.00 美元，并在 9 月 5 日的报告中给予该公司 “买入” 评级。韦斯评级在周一的研究报告中重申了对 Syndax Pharmaceuticals 的 “卖出（d-）” 评级。斯蒂费尔·尼古拉斯在 9 月 10 日的研究报告中启动了对 Syndax Pharmaceuticals 的覆盖。他们给予该股票 “买入” 评级，并设定了 44.00 美元的目标价。最后，华尔街 Zen 在周六的研究报告中将 Syndax Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。一位研究分析师对该股票给予了强烈买入评级，九位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Syndax Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 37.20 美元。</p>
<p><strong>阅读我们最新的 SNDX 股票分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席执行官 Michael A. Metzger 在 9 月 8 日星期一出售了 157,307 股该公司的股票。该股票以平均价格 16.41 美元出售，总交易额为 2,581,407.87 美元。出售后，首席执行官持有 298,661 股该公司的股票，价值 4,901,027.01 美元。此次交易使其持股减少了 34.50%。该交易已在向证券交易委员会的法律文件中披露，相关文件可通过此链接获取。内部人士持有该公司 4.10% 的股份。</p>
<h2>Syndax Pharmaceuticals 简介</h2>
<p>（免费报告）</p>
<p>Syndax Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，开发用于癌症治疗的疗法。其主要产品候选药物包括 revumenib，一种强效、选择性的、针对 menin-MLL 结合相互作用的小分子抑制剂，用于治疗 KMT2A 重排的急性白血病和实体瘤；以及 SNDX-6352 或 axatilimab，一种单克隆抗体，阻断集落刺激因子 1（CSF-1）受体，用于治疗慢性移植物抗宿主病（cGVHD）和特发性肺纤维化（IPF）患者。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Syndax Pharmaceuticals</li>
<li>NYSE 股票为投资者提供多种优质选择</li>
<li>比尔和梅琳达·盖茨基金会出售 MSFT 股票——投资者应该担心吗？</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>MarketBeat 周回顾 – 12/1 - 12/5</li>
<li>深入了解买卖差价</li>
<li>Rocket Lab 的大反弹？分析师建议此次下跌是个机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Syndax Pharmaceuticals 吗？</h2>
<p>在你考虑 Syndax Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Syndax Pharmaceuticals 并不在名单上。</p>
<p>虽然 Syndax Pharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Syndax制药

<p>Tema Etfs LLC 在第二季度将其在 Syndax Pharmaceuticals 的股份增加了 307.7%，持有 86,301 股，价值 808,000 美元。其他投资者也增加了他们的持股。Syndax 的股票上涨了 2.9%，市值为 17.7 亿美元。分析师的评级不一，普遍共识为 “适度买入”，平均目标价为 37.20 美元。首席执行官 Michael Metzger 出售了价值 258 万美元的股份</p>

<p>Tema Etfs LLC increased its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 307.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,301 shares of the company's stock after acquiring an additional 65,132 shares during the quarter. Tema Etfs LLC owned about 0.10% of Syndax Pharmaceuticals worth $808,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Tema Etfs LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Syndax Pharmaceuticals, Inc.（NASDAQ:SNDX - 免费报告）的股份增加了 307.7%。该机构投资者在本季度额外收购了 65,132 股后，持有该公司 86,301 股股票。Tema Etfs LLC 在最近一个季度末持有 Syndax Pharmaceuticals 约 0.10% 的股份，价值 808,000 美元。</p>
</div><p>Get <strong>Syndax Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
</div><p>Other large investors also recently bought and sold shares of the company. Franklin Resources Inc. increased its position in shares of Syndax Pharmaceuticals by 14.5% during the second quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company's stock worth $22,098,000 after purchasing an additional 298,272 shares in the last quarter. Geode Capital Management LLC increased its position in Syndax Pharmaceuticals by 1.3% during the second quarter. Geode Capital Management LLC now owns 2,049,350 shares of the company's stock worth $19,195,000 after buying an additional 26,365 shares during the period. Aisling Capital Management LP lifted its stake in Syndax Pharmaceuticals by 28.5% in the second quarter. Aisling Capital Management LP now owns 1,316,806 shares of the company's stock valued at $12,325,000 after buying an additional 291,806 shares during the last quarter. Algert Global LLC boosted its holdings in shares of Syndax Pharmaceuticals by 12.6% in the first quarter. Algert Global LLC now owns 884,600 shares of the company's stock valued at $10,867,000 after acquiring an additional 98,968 shares during the period. Finally, Candriam S.C.A. boosted its holdings in shares of Syndax Pharmaceuticals by 49.9% in the second quarter. Candriam S.C.A. now owns 675,085 shares of the company's stock valued at $6,322,000 after acquiring an additional 224,650 shares during the period.</p>
<div class="lb-trans"><p>其他大型投资者最近也买卖了该公司的股票。富兰克林资源公司在第二季度将其在 Syndax Pharmaceuticals 的股份增加了 14.5%。富兰克林资源公司现在拥有 2,359,677 股该公司的股票，价值 22,098,000 美元，此前在上个季度额外购买了 298,272 股。Geode Capital Management LLC 在第二季度将其在 Syndax Pharmaceuticals 的股份增加了 1.3%。Geode Capital Management LLC 现在拥有 2,049,350 股该公司的股票，价值 19,195,000 美元，此前在此期间额外购买了 26,365 股。Aisling Capital Management LP 在第二季度将其在 Syndax Pharmaceuticals 的股份增加了 28.5%。Aisling Capital Management LP 现在拥有 1,316,806 股该公司的股票，价值 12,325,000 美元，此前在上个季度额外购买了 291,806 股。Algert Global LLC 在第一季度将其在 Syndax Pharmaceuticals 的持股增加了 12.6%。Algert Global LLC 现在拥有 884,600 股该公司的股票，价值 10,867,000 美元，此前在此期间额外收购了 98,968 股。最后，Candriam S.C.A. 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 49.9%。Candriam S.C.A. 现在拥有 675,085 股该公司的股票，价值 6,322,000 美元，此前在此期间额外收购了 224,650 股。</p>
</div><h2>Syndax Pharmaceuticals Stock Up 2.9%</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 股票上涨 2.9%</h2>
</div><p>SNDX opened at $20.32 on Friday. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $20.59. The stock has a market capitalization of $1.77 billion, a P/E ratio of -5.63 and a beta of 0.48. The business has a 50 day simple moving average of $16.30 and a 200-day simple moving average of $13.57.</p>
<div class="lb-trans"><p>SNDX 周五开盘价为 20.32 美元。该公司的债务与股本比率为 2.78，流动比率为 4.64，速动比率为 4.42。Syndax Pharmaceuticals, Inc. 的 12 个月最低价为 8.58 美元，最高价为 20.59 美元。该股票的市值为 17.7 亿美元，市盈率为 -5.63，贝塔值为 0.48。该公司的 50 日简单移动平均线为 16.30 美元，200 日简单移动平均线为 13.57 美元。</p>
</div><p>Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.04. The firm had revenue of $45.87 million during the quarter, compared to analysts' expectations of $49.08 million. Syndax Pharmaceuticals had a negative return on equity of 160.60% and a negative net margin of 279.31%.Syndax Pharmaceuticals's revenue was up 266.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.98) earnings per share. On average, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals（NASDAQ:SNDX - 获取免费报告）上次发布季度财报是在 11 月 3 日星期一。该公司报告的每股收益（EPS）为（0.70）美元，超过了市场共识预期的（0.74）美元，超出 0.04 美元。该公司在本季度的收入为 4587 万美元，而分析师预期为 4908 万美元。Syndax Pharmaceuticals 的股本回报率为 -160.60%，净利润率为 -279.31%。与去年同期相比，Syndax Pharmaceuticals 的收入增长了 266.4%。在去年同期，该公司每股收益为（0.98）美元。平均而言，股票分析师预计 Syndax Pharmaceuticals, Inc. 在当前财政年度的每股收益将为 -3.72 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research firms recently commented on SNDX. Barclays upped their price target on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, November 24th. The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a &#34;buy&#34; rating in a report on Friday, September 5th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Syndax Pharmaceuticals in a research note on Monday. Stifel Nicolaus initiated coverage on Syndax Pharmaceuticals in a research report on Wednesday, September 10th. They issued a &#34;buy&#34; rating and a $44.00 price target on the stock. Finally, Wall Street Zen cut Syndax Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $37.20.</p>
<div class="lb-trans"><p>几家研究公司最近对 SNDX 进行了评论。巴克莱将 Syndax Pharmaceuticals 的股票目标价从 22.00 美元上调至 35.00 美元，并在 11 月 24 日的研究报告中给予该公司 “增持” 评级。高盛集团将 Syndax Pharmaceuticals 的股票目标价从 20.00 美元上调至 24.00 美元，并在 9 月 5 日的报告中给予该公司 “买入” 评级。韦斯评级在周一的研究报告中重申了对 Syndax Pharmaceuticals 的 “卖出（d-）” 评级。斯蒂费尔·尼古拉斯在 9 月 10 日的研究报告中启动了对 Syndax Pharmaceuticals 的覆盖。他们给予该股票 “买入” 评级，并设定了 44.00 美元的目标价。最后，华尔街 Zen 在周六的研究报告中将 Syndax Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。一位研究分析师对该股票给予了强烈买入评级，九位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Syndax Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 37.20 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on SNDX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 SNDX 股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO Michael A. Metzger sold 157,307 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the sale, the chief executive officer owned 298,661 shares of the company's stock, valued at $4,901,027.01. The trade was a 34.50% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Michael A. Metzger 在 9 月 8 日星期一出售了 157,307 股该公司的股票。该股票以平均价格 16.41 美元出售，总交易额为 2,581,407.87 美元。出售后，首席执行官持有 298,661 股该公司的股票，价值 4,901,027.01 美元。此次交易使其持股减少了 34.50%。该交易已在向证券交易委员会的法律文件中披露，相关文件可通过此链接获取。内部人士持有该公司 4.10% 的股份。</p>
</div><h2>Syndax Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，开发用于癌症治疗的疗法。其主要产品候选药物包括 revumenib，一种强效、选择性的、针对 menin-MLL 结合相互作用的小分子抑制剂，用于治疗 KMT2A 重排的急性白血病和实体瘤；以及 SNDX-6352 或 axatilimab，一种单克隆抗体，阻断集落刺激因子 1（CSF-1）受体，用于治疗慢性移植物抗宿主病（cGVHD）和特发性肺纤维化（IPF）患者。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Syndax Pharmaceuticals</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>MarketBeat Week in Review – 12/1 - 12/5</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Syndax Pharmaceuticals</li>
<li>NYSE 股票为投资者提供多种优质选择</li>
<li>比尔和梅琳达·盖茨基金会出售 MSFT 股票——投资者应该担心吗？</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>MarketBeat 周回顾 – 12/1 - 12/5</li>
<li>深入了解买卖差价</li>
<li>Rocket Lab 的大反弹？分析师建议此次下跌是个机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SNDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Syndax Pharmaceuticals 吗？</h2>
</div><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Syndax Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Syndax Pharmaceuticals 并不在名单上。</p>
</div><p>While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Syndax Pharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Syndax 制药公司 $SNDX 的股票被 Tema Etfs LLC 收购